Toxicokinetics of new psychoactive substances: Plasma protein binding, metabolic stability, and human phase I metabolism of the synthetic cannabinoid WIN 55,212-2 studied using in vitro tools and LC-HR-MS/MS

Marie Mardal, Emma Gracia-Lor, Svenja Leibnitz, Sara Castiglioni, Markus R. Meyer

Research output: Contribution to journalArticle

Abstract

The new psychoactive substance WIN 55,212-2 ((R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo-[1,2,3-de]-1,4-benzoxazin-6-yl]-1-napthalenylmethanone) is a potent synthetic cannabinoid receptor agonist. The metabolism of WIN 55,212-2 in man has never been reported. Therefore, the aim of this study was to identify the human in vitro metabolites of WIN 55,212-2 using pooled human liver microsomes and liquid chromatography-high resolution-tandem mass spectrometry (LC-HR-MS/MS) to provide targets for toxicological, doping, and environmental screening procedures. Moreover, a metabolic stability study in pooled human liver microsomes (pHLM) was carried out. In total, 19 metabolites were identified and the following partly overlapping metabolic steps were deduced: degradation of the morpholine ring via hydroxylation, N- and O-dealkylation, and oxidative deamination, hydroxylations on either the naphthalene or morpholine ring or the alkyl spacer with subsequent oxidation, epoxide formation with subsequent hydrolysis, or combinations. In conclusion, WIN 55,212-2 was extensively metabolized in human liver microsomes incubations and the calculated hepatic clearance was comparably high, indicating a fast and nearly complete metabolism in vivo. This is in line with previous findings on other synthetic cannabinoids.

Original languageEnglish
Pages (from-to)1039-1048
JournalDrug Testing and Analysis
Volume8
DOIs
Publication statusPublished - 2016

Fingerprint

Cannabinoids
Protein Binding
Metabolism
Blood Proteins
metabolite
Liver Microsomes
metabolism
Liver
plasma
Hydroxylation
protein
Metabolites
naphthalene
liquid chromatography
hydrolysis
mass spectrometry
incubation
Artificial Receptors
Dealkylation
Cannabinoid Receptor Agonists

Keywords

  • Designer drugs
  • Human liver microsomes
  • LC-HR-MS/MS
  • Metabolic stability
  • Synthetic cannabinoids

ASJC Scopus subject areas

  • Analytical Chemistry
  • Environmental Chemistry
  • Pharmaceutical Science
  • Spectroscopy

Cite this

@article{ce01623c425f48aa98f166093dde88f9,
title = "Toxicokinetics of new psychoactive substances: Plasma protein binding, metabolic stability, and human phase I metabolism of the synthetic cannabinoid WIN 55,212-2 studied using in vitro tools and LC-HR-MS/MS",
abstract = "The new psychoactive substance WIN 55,212-2 ((R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo-[1,2,3-de]-1,4-benzoxazin-6-yl]-1-napthalenylmethanone) is a potent synthetic cannabinoid receptor agonist. The metabolism of WIN 55,212-2 in man has never been reported. Therefore, the aim of this study was to identify the human in vitro metabolites of WIN 55,212-2 using pooled human liver microsomes and liquid chromatography-high resolution-tandem mass spectrometry (LC-HR-MS/MS) to provide targets for toxicological, doping, and environmental screening procedures. Moreover, a metabolic stability study in pooled human liver microsomes (pHLM) was carried out. In total, 19 metabolites were identified and the following partly overlapping metabolic steps were deduced: degradation of the morpholine ring via hydroxylation, N- and O-dealkylation, and oxidative deamination, hydroxylations on either the naphthalene or morpholine ring or the alkyl spacer with subsequent oxidation, epoxide formation with subsequent hydrolysis, or combinations. In conclusion, WIN 55,212-2 was extensively metabolized in human liver microsomes incubations and the calculated hepatic clearance was comparably high, indicating a fast and nearly complete metabolism in vivo. This is in line with previous findings on other synthetic cannabinoids.",
keywords = "Designer drugs, Human liver microsomes, LC-HR-MS/MS, Metabolic stability, Synthetic cannabinoids",
author = "Marie Mardal and Emma Gracia-Lor and Svenja Leibnitz and Sara Castiglioni and Meyer, {Markus R.}",
year = "2016",
doi = "10.1002/dta.1938",
language = "English",
volume = "8",
pages = "1039--1048",
journal = "Drug Testing and Analysis",
issn = "1942-7603",
publisher = "John Wiley and Sons Ltd",

}

TY - JOUR

T1 - Toxicokinetics of new psychoactive substances

T2 - Plasma protein binding, metabolic stability, and human phase I metabolism of the synthetic cannabinoid WIN 55,212-2 studied using in vitro tools and LC-HR-MS/MS

AU - Mardal, Marie

AU - Gracia-Lor, Emma

AU - Leibnitz, Svenja

AU - Castiglioni, Sara

AU - Meyer, Markus R.

PY - 2016

Y1 - 2016

N2 - The new psychoactive substance WIN 55,212-2 ((R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo-[1,2,3-de]-1,4-benzoxazin-6-yl]-1-napthalenylmethanone) is a potent synthetic cannabinoid receptor agonist. The metabolism of WIN 55,212-2 in man has never been reported. Therefore, the aim of this study was to identify the human in vitro metabolites of WIN 55,212-2 using pooled human liver microsomes and liquid chromatography-high resolution-tandem mass spectrometry (LC-HR-MS/MS) to provide targets for toxicological, doping, and environmental screening procedures. Moreover, a metabolic stability study in pooled human liver microsomes (pHLM) was carried out. In total, 19 metabolites were identified and the following partly overlapping metabolic steps were deduced: degradation of the morpholine ring via hydroxylation, N- and O-dealkylation, and oxidative deamination, hydroxylations on either the naphthalene or morpholine ring or the alkyl spacer with subsequent oxidation, epoxide formation with subsequent hydrolysis, or combinations. In conclusion, WIN 55,212-2 was extensively metabolized in human liver microsomes incubations and the calculated hepatic clearance was comparably high, indicating a fast and nearly complete metabolism in vivo. This is in line with previous findings on other synthetic cannabinoids.

AB - The new psychoactive substance WIN 55,212-2 ((R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo-[1,2,3-de]-1,4-benzoxazin-6-yl]-1-napthalenylmethanone) is a potent synthetic cannabinoid receptor agonist. The metabolism of WIN 55,212-2 in man has never been reported. Therefore, the aim of this study was to identify the human in vitro metabolites of WIN 55,212-2 using pooled human liver microsomes and liquid chromatography-high resolution-tandem mass spectrometry (LC-HR-MS/MS) to provide targets for toxicological, doping, and environmental screening procedures. Moreover, a metabolic stability study in pooled human liver microsomes (pHLM) was carried out. In total, 19 metabolites were identified and the following partly overlapping metabolic steps were deduced: degradation of the morpholine ring via hydroxylation, N- and O-dealkylation, and oxidative deamination, hydroxylations on either the naphthalene or morpholine ring or the alkyl spacer with subsequent oxidation, epoxide formation with subsequent hydrolysis, or combinations. In conclusion, WIN 55,212-2 was extensively metabolized in human liver microsomes incubations and the calculated hepatic clearance was comparably high, indicating a fast and nearly complete metabolism in vivo. This is in line with previous findings on other synthetic cannabinoids.

KW - Designer drugs

KW - Human liver microsomes

KW - LC-HR-MS/MS

KW - Metabolic stability

KW - Synthetic cannabinoids

UR - http://www.scopus.com/inward/record.url?scp=84958012476&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958012476&partnerID=8YFLogxK

U2 - 10.1002/dta.1938

DO - 10.1002/dta.1938

M3 - Article

AN - SCOPUS:84958012476

VL - 8

SP - 1039

EP - 1048

JO - Drug Testing and Analysis

JF - Drug Testing and Analysis

SN - 1942-7603

ER -